Remove BMI Remove Exercise Remove Preserved Ejection Fraction
article thumbnail

Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP?HF II trial

European Journal of Heart Failure

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased. Overall, 60.9%

article thumbnail

Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial

Circulation

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. mg improved symptoms, physical limitations and exercise function, and reduced inflammation and body weight. Circulation, Ahead of Print.

article thumbnail

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2. These individuals tend to have a better prognosis when compared to both individuals with normal weight (BMI of 18.5 to 25 kg/m2) and underweight (BMI less than 18.5

Obesity 52
article thumbnail

Abstract 4118122: Effect of Beta Blockers on Exercise Capacity, Diastolic Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction

Circulation

The primary outcomes were exercise capacity, diastolic function, and quality of life at baseline evaluation. Patients studied were older (68 years old), white (90%), obese (average BMI 34 kg/m2) individuals with an average LVEF of 61%. Patients were divided into two groups based on BB use at trial enrollment.

article thumbnail

Semaglutide Leads to Greater Weight Loss in Women than Men with HF, Improves HF Symptoms in Both Sexes

DAIC

The analysis sought to determine whether phenotypic features and treatment effects of semaglutide vary by sex in obesity-related heart failure ( HF ) with preserved ejection fraction (HFpEF). Our study sheds light on these differences and the consistent benefits of semaglutide for women and men.”